PXMD — Kuvatris Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
PaxMedica rises on Malawi's request for access to sleeping sickness drug
Brief: Paxmedica Receives Emergency Request For Iv Suramin From African Health Ministry For Use In Treating Fatal Sleeping Sickness
Brief: PaxMedica Achieves Key Milestone In The Development Of PAX-101 And Provides Update On Potential NDA Submission
Brief: Paxmedica Announces Pricing Of $7.0 Million Public Offering
Brief: Paxmedica Featured In Syndicated Broadcast Highlighting FDA Type-B Meeting To Review Pax-101
U.S. STOCKS ON THE MOVE-US banks, Splunk, ReAlpha Tech
Brief: PaxMedica Acquires Suramin Research Assets From Rediscovery Life Sciences To Accelerate NDA Submission For Pax-101
Brief: Paxmedica Acquires Suramin Research Assets From Rediscovery Life Sciences To Accelerate NDA Submission For Pax-101
Brief: PaxMedica Announces 1-For-17 Reverse Stock Split
Brief: Paxmedica Appoints David Hough As Chief Medical Officer
Brief: Paxmedica On Aug 2 Got Written Notification From Nasdaq Indicating That Co Was Not In Compliance With Minimum Closing Bid Price Requirement
U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX
U.S. STOCKS ON THE MOVE-PaxMedica, Heron, Belite Bio
PaxMedica up as sleeping sickness medication meets primary study goal
Brief: Paxmedica Announces Positive Top Line Results From Pax-101 Phase 3 African Sleeping Sickness Study
Brief: PaxMedica Grants Exclusive Pharmacy Distribution Rights For PAX-101 To Vox Nova, LLC
Brief: Paxmedica Receives Letter From Nasdaq That Co Has Not Regained Compliance With Minimum Market Value Requirement
Brief: Paxmedica Submits Clinical Trial Request In Autism Spectrum Disorder
PaxMedica rises on research agreement with PoloMar Health